TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programs. The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the first approved cell-based product in Europe, and is currently being sold across Europe. TiGenix’s adipose derived allogeneic stem cell platform has been extensively validated. The company is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease, has successfully concluded a Phase IIa trial in rheumatoid arthritis, as well as a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
9th edition European Smallcap Event,
April 7-8, Paris, France
9th Annual World Stem Cell & Regenerative Medicine Congress
May 20-22, London, UK
BioEquity Europe 2014
May 21-22, Amsterdam, the Netherlands
Bio International Convention,
June 23-26, San Diego, U.S.